

## Checklist for Reporting Human Islet Preparations Used in Research

<b>Manuscript DOI:</b> DB20-0204	
<b>Title:</b> Epigenetic changes in Langerhans islets preceding the onset of diabetes	
<b>Author list:</b> Meriem Ouni, PhD, Sophie Saussenthaler, MSc*, Fabian Eichelmann, PhD*, Markus Jähnert, MSc, Clemens Wittenbecher PhD, Tina Rönn PhD, Lisa Zellner, MSc, Pascal Gottmann, PhD, Charlotte Ling, PhD, Matthias B. Schulze, DrPH and Annette Schürmann, PhD	
<b>Corresponding author:</b> Prof. Dr. Annette Schürmann	<b>Email address:</b> schuermann@dife.de

Islet preparation	1	2	3	4	5	6	7	8 <sup>a</sup>
MANDATORY INFORMATION								
Unique identifier	49							
Donor age (years)	69							
Donor sex (M/F)	Male							
Donor BMI (kg/m <sup>2</sup> )	31.3							

Donor HbA <sub>1c</sub> or other measure of blood glucose control	42							
Origin/source of islets <sup>b</sup>	The Nordic Network For Clinical Islet Transplantation							
Islet isolation centre	Uppsala							
Donor history of diabetes? Yes/No	no							
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)								
Glucose-lowering therapy at time of death <sup>c</sup>								

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) <sup>d</sup>								
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>								
Handpicked to purity? Yes/No								
Additional notes								

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results